Showing 8,841 - 8,860 results of 10,820 for search 'significantly ((((lower decrease) OR (we decrease))) OR (mean decrease))', query time: 0.34s Refine Results
  1. 8841

    Image 1_Differential Ca2+ handling by isolated synaptic and non-synaptic mitochondria: roles of Ca2+ buffering and efflux.tif by Jyotsna Mishra (3703195)

    Published 2025
    “…When both mitochondrial fractions were exposed to increasing mCa<sup>2+</sup> loads we observed decreased mCa<sup>2+</sup> sequestration in synaptic mitochondria as assessed by a significant increase in the steady-state free extra matrix Ca<sup>2+</sup> (ss[Ca<sup>2+</sup>]<sub>e</sub>) compared to non-synaptic mitochondria. …”
  2. 8842

    Image 2_Differential Ca2+ handling by isolated synaptic and non-synaptic mitochondria: roles of Ca2+ buffering and efflux.tif by Jyotsna Mishra (3703195)

    Published 2025
    “…When both mitochondrial fractions were exposed to increasing mCa<sup>2+</sup> loads we observed decreased mCa<sup>2+</sup> sequestration in synaptic mitochondria as assessed by a significant increase in the steady-state free extra matrix Ca<sup>2+</sup> (ss[Ca<sup>2+</sup>]<sub>e</sub>) compared to non-synaptic mitochondria. …”
  3. 8843

    Image 3_Differential Ca2+ handling by isolated synaptic and non-synaptic mitochondria: roles of Ca2+ buffering and efflux.tif by Jyotsna Mishra (3703195)

    Published 2025
    “…When both mitochondrial fractions were exposed to increasing mCa<sup>2+</sup> loads we observed decreased mCa<sup>2+</sup> sequestration in synaptic mitochondria as assessed by a significant increase in the steady-state free extra matrix Ca<sup>2+</sup> (ss[Ca<sup>2+</sup>]<sub>e</sub>) compared to non-synaptic mitochondria. …”
  4. 8844

    Ybx1 regulation of its target mRNAs is m<sup>5</sup>C-depdendent (Related to Fig 5). by Jian Zhang (1682)

    Published 2025
    “…Data are presented as mean ± SEM: at least 3 replicates were analyzed for each experiment (<i>n</i> = 3); ns, not significant; by unpaired Student <i>t</i> test. …”
  5. 8845

    Fig 4 - by Nehal Shawky Nagy (17721213)

    Published 2024
    “…Values are expressed as mean ± SEM; n = 3 rats for each group. Different superscripts on the columns are significantly different at p≤0.05.…”
  6. 8846

    Data Sheet 1_Association of oxidative balance score with all-cause and cardiovascular mortality among patients with cardio-renal-metabolic disease.docx by Yucui Lin (21598376)

    Published 2025
    “…Moreover, Higher OBS quartiles were linked to a decreased risk of cardiovascular mortality, while no significant reduction was observed in the lower quartiles [model 3: Q2, Q3, Q4: aHR (95CI%) = 0.96(0.77–1.19), 0.78 (0.63–0.97), 0.70 (0.53–0.93), respectively; P for trend = 0.003]. …”
  7. 8847

    Supplementary Material for: Seraph-100 hemoperfusion for management of severe COVID-19: Assessment of serum and plasma analytes pre- and post-filtration by Rouse M. (20413172)

    Published 2024
    “…Paired t-tests identified 25 additional analytes that showed significant decreases (p<0.05) only without Bonferroni correction. …”
  8. 8848

    <i>Irresistible</i><sup><i>p173</i></sup> is an allele of the Cadherin-encoding gene <i>cdh16.</i> by Susannah S. Schloss (21238775)

    Published 2025
    “…<b>(G)</b> <i>cdh16</i><sup><i>p173</i></sup>/<i>cdh16</i><sup><i>co79</i></sup> transheterozygotes (<i>n</i> = 19) have significantly lower habituation percentages <i>p</i> < 0.0001 compared to wild types (<i>n</i> = 17), <i>cdh16</i><sup><i>co79</i></sup> heterozygotes (<i>n</i> = 10), and <i>cdh16</i><sup><i>p173</i></sup> heterozygotes (<i>n</i> = 25). …”
  9. 8849

    JAK/STAT signaling promotes high global translation rates in CySCs. by Ruoxu Wang (9312306)

    Published 2025
    “…(<b>I</b>) Quan<i>t</i>ification of OPP incorporation in 1st row cyst cells (CySCs) normalized to levels in the hub. CySCs have significantly lower OPP levels in <i>Stat92e</i> mutant testes than in controls (<i>N</i> > 100 cells from ≥ 8 testes, Student <i>t</i> test, * <i>P</i> < 0.05). …”
  10. 8850

    Table6_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  11. 8851

    Table4_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  12. 8852

    Table2_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  13. 8853

    Table8_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  14. 8854

    Table5_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  15. 8855

    Table3_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  16. 8856

    Table7_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  17. 8857

    Table1_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.DOCX by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  18. 8858

    Table 1_Stroke-associated pneumonia with low PaO2/FiO2 ratio in acute large vessel occlusion after endovascular therapy: risk factors and prognosis.docx by Kun Tang (75641)

    Published 2025
    “…A deterioration in SAP manifests itself in a decreased partial pressure oxygen (PaO<sub>2</sub>)/fraction of inspired oxygen (FiO<sub>2</sub>) ratio, indicating gas exchange dysfunction. …”
  19. 8859

    Table 1_Outcomes of mini-monovision with monofocal, enhanced monofocal and extended depth-of-focus intraocular lenses.docx by Issac Levy (20762594)

    Published 2025
    “…</p>Conclusion<p>While enhanced monofocal and EDOF IOLs may provide slightly better binocular intermediate visual outcomes and higher spectacle independence compared to monofocal lenses with regards to mini-monovision and intermediate vision performance, the differences are not statistically significant. All three IOL types exhibit high patient satisfaction rates when choosing a mini-monovision approach with decreased dependence on spectacles.…”
  20. 8860

    Presentation 1_Gender and age differences in the global burden of peptic ulcers: an analysis based on GBD data from 1990 to 2021.zip by Ruirui Tan (21188585)

    Published 2025
    “…In terms of future trends, the global incidence of PU is projected to continue decreasing over the next 15 years. The global prevalence is expected to improve, while PU-related mortality is likely to plateau without significant increases or decreases.…”